Key terms
About LPCN
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LPCN news
Apr 11
7:06am ET
Lipocine’s LPCN 2401 shows positive Phase 2 results in obesity trial
Mar 28
8:05am ET
Lipocine’s LPCN 1148 shows positive results in Phase 2 cirrhosis study
Mar 25
8:09am ET
Lipocine announces first cohort dosed in LPCN 1154
Feb 12
4:24pm ET
Lipocine Announces Key Study Dosing for Postpartum Depression Treatment
Feb 06
8:04am ET
Lipocine confirms dosing regimen for pivotal study of LPCN 1154
Feb 02
8:05am ET
Lipocine to continue commercialization of Tlando through Verity Pharma
Jan 19
3:09am ET
Lipocine Strikes Major Deal for TLANDO Franchise Rights
Jan 18
8:06am ET
Lipocine announces license agreement for TLANDO in the U.S.
No recent press releases are available for LPCN
LPCN Financials
Key terms
Ad Feedback
LPCN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LPCN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
